# Nuo Therapeutics, Inc.: overview AURX · OTC · CIK 1091596 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/aurx.md) · [Financials](/companies/aurx/financials.md) · [Filings](/companies/aurx/filings.md) · [Insiders](/companies/aurx/insiders.md) Latest reported revenue: [$1.8m](/filings/0001437749-26-028053.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-028053). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [371](/filings/0001437749-25-032437.md) | [395 d](/filings/0001437749-26-010360.md) | [484](/filings/0001437749-26-017104.md) | [700](/filings/0001437749-26-028053.md) | [1,032](/filings/0001437749-25-032437.md) | [1,097 d](/filings/0001437749-26-010360.md) | [1,302](/filings/0001437749-26-017104.md) | [1,769](/filings/0001437749-26-028053.md) | | Gross margin | % | [72.9%](/filings/0001437749-25-032437.md) | [78.1% d](/filings/0001437749-26-010360.md) | [75.0%](/filings/0001437749-26-017104.md) | [77.2%](/filings/0001437749-26-028053.md) | [60.6%](/filings/0001437749-25-032437.md) | [62.8% d](/filings/0001437749-26-010360.md) | [65.3%](/filings/0001437749-26-017104.md) | [66.1%](/filings/0001437749-26-028053.md) | | Operating margin | % | [(155.6%)](/filings/0001437749-25-032437.md) | [(159.4%) d](/filings/0001437749-26-010360.md) | [(153.8%)](/filings/0001437749-26-017104.md) | [(93.1%)](/filings/0001437749-26-028053.md) | [(52.3%)](/filings/0001437749-25-032437.md) | [(52.8%) d](/filings/0001437749-26-010360.md) | [(34.3%)](/filings/0001437749-26-017104.md) | [(9.4%)](/filings/0001437749-26-028053.md) | | Net margin | % | [(155.9%)](/filings/0001437749-25-032437.md) | [(125.8%) d](/filings/0001437749-26-010360.md) | [(154.0%)](/filings/0001437749-26-028053.md) | [(92.8%)](/filings/0001437749-26-028053.md) | [(52.1%)](/filings/0001437749-25-032437.md) | [(52.7%) d](/filings/0001437749-26-010360.md) | [(47.5%)](/filings/0001437749-26-028053.md) | [(15.7%)](/filings/0001437749-26-028053.md) | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(638) d](/filings/0001437749-25-032437.md) | [(491) d](/filings/0001437749-26-010360.md) | [(228)](/filings/0001437749-26-017104.md) | [261 d](/filings/0001437749-26-028053.md) | [(707) d](/filings/0001437749-25-032437.md) | [(466) d](/filings/0001437749-26-010360.md) | [(785)](/filings/0001437749-26-017104.md) | [(490) d](/filings/0001437749-26-028053.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001437749-23-010351.md) | [112](/filings/0001437749-24-012587.md) | [609](/filings/0001437749-25-010379.md) | [1,365](/filings/0001437749-26-010360.md) | [3,314](/filings/0001437749-26-010360.md) | | Gross margin | % | not reported | [82.9%](/filings/0001437749-24-012587.md) | [79.3%](/filings/0001437749-25-010379.md) | [77.8%](/filings/0001437749-26-010360.md) | [66.9%](/filings/0001437749-26-010360.md) | | Operating margin | % | not reported | [(2958.2%)](/filings/0001437749-24-012587.md) | [(520.6%)](/filings/0001437749-25-010379.md) | [(180.0%)](/filings/0001437749-26-010360.md) | [(76.0%)](/filings/0001437749-26-010360.md) | | Net margin | % | not reported | [(2825.6%)](/filings/0001437749-24-012587.md) | [(521.2%)](/filings/0001437749-25-010379.md) | [(170.2%)](/filings/0001437749-26-010360.md) | [(75.8%)](/filings/0001437749-26-010360.md) | | Diluted EPS | $ per share | [(0.03)](/filings/0001437749-22-009050.md) | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(120)](/filings/0001437749-23-010351.md) | [(3,766)](/filings/0001437749-24-012587.md) | [(3,175)](/filings/0001437749-25-010379.md) | [(2,387)](/filings/0001437749-26-010360.md) | [(1,140)](/filings/0001437749-26-010360.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aurx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Ancora Advisors LLC](/funds/1446114.md) | 2026-06-30 | $4.3k | 4,700 | | Unchanged | ## Recent filings [All 858 filings](/companies/aurx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-06 | 20:57 ET | [8-K](/filings/0001437749-26-032242.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001437749-26-032242 | | 2026-08-17 | 11:55 ET | [8-K](/filings/0001437749-26-028109.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-028109 | | 2026-08-14 | 21:10 ET | [10-Q](/filings/0001437749-26-028053.md) | Quarterly report, period 2026-06-30 | 0001437749-26-028053 | | 2026-06-03 | 15:04 ET | [SCHEDULE 13D/A](/filings/0001674752-26-000002.md) | Ownership report, active investor, amended | 0001674752-26-000002 | | 2026-06-03 | 21:41 ET | [8-K](/filings/0001437749-26-019199.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001437749-26-019199 | | 2026-05-14 | 21:11 ET | [8-K](/filings/0001437749-26-017116.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-017116 | | 2026-05-14 | 21:00 ET | [10-Q](/filings/0001437749-26-017104.md) | Quarterly report, period 2026-03-31 | 0001437749-26-017104 | | 2026-03-30 | 21:38 ET | [10-K](/filings/0001437749-26-010360.md) | Annual report, period 2025-12-31 | 0001437749-26-010360 | | 2026-01-26 | 23:05 ET | [SCHEDULE 13D/A](/filings/0001437749-26-002120.md) | Ownership report, active investor, amended | 0001437749-26-002120 | | 2026-01-26 | 21:25 ET | [8-K](/filings/0001437749-26-002078.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001437749-26-002078 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-010360.md), filed Mar 30, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/665f958c-fa1e-4c3b-9f92-fd7a88ebf970) ## About the filer - CIK: 1091596 - Tickers: AURX - Exchange: OTC - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.